SG11202012773QA - Peptide compounds and therapeutic uses of same - Google Patents

Peptide compounds and therapeutic uses of same

Info

Publication number
SG11202012773QA
SG11202012773QA SG11202012773QA SG11202012773QA SG11202012773QA SG 11202012773Q A SG11202012773Q A SG 11202012773QA SG 11202012773Q A SG11202012773Q A SG 11202012773QA SG 11202012773Q A SG11202012773Q A SG 11202012773QA SG 11202012773Q A SG11202012773Q A SG 11202012773QA
Authority
SG
Singapore
Prior art keywords
same
therapeutic uses
peptide compounds
peptide
compounds
Prior art date
Application number
SG11202012773QA
Inventor
Eran Ovadia
Avi Ben-Shimon
Original Assignee
Immunity Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunity Pharma Ltd filed Critical Immunity Pharma Ltd
Publication of SG11202012773QA publication Critical patent/SG11202012773QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
SG11202012773QA 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same SG11202012773QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL26055518 2018-07-11
PCT/IL2019/050774 WO2020012478A2 (en) 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same

Publications (1)

Publication Number Publication Date
SG11202012773QA true SG11202012773QA (en) 2021-01-28

Family

ID=69141375

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012773QA SG11202012773QA (en) 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same

Country Status (15)

Country Link
US (1) US11912790B2 (en)
EP (1) EP3820882A2 (en)
JP (2) JP7395517B2 (en)
KR (1) KR20210045397A (en)
CN (1) CN112351989B (en)
AU (1) AU2019300567A1 (en)
BR (1) BR112020024748A2 (en)
CA (1) CA3100961A1 (en)
CO (1) CO2021001290A2 (en)
EA (1) EA202190249A1 (en)
IL (1) IL280101A (en)
MX (1) MX2021000264A (en)
SG (1) SG11202012773QA (en)
WO (1) WO2020012478A2 (en)
ZA (1) ZA202100587B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7395517B2 (en) 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド Peptide compounds and their therapeutic uses
IL272074A (en) * 2020-01-15 2021-07-29 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
JPS4843906B1 (en) * 1970-08-11 1973-12-21
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
GB9711148D0 (en) * 1997-05-31 1997-07-23 Peptide Therapeutics Ltd Human MAFA
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
EP1381839A4 (en) 2001-04-03 2005-10-12 Univ Leland Stanford Junior Method of imaging cell death in vivo
US20040204340A1 (en) * 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
WO2006021954A2 (en) 2004-08-23 2006-03-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
AU2006210895A1 (en) * 2005-02-01 2006-08-10 Attenuon, Llc Compositions containing the anti-angiogenic PHSCN-peptide
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
EP2478009B1 (en) * 2009-09-17 2016-06-01 Ramot at Tel-Aviv University Ltd. Peptides for the treatment of oxidative stress related disorders
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
US20130331297A1 (en) 2010-07-16 2013-12-12 Avantgen, Inc. Novel peptides and uses thereof
EP2655612B1 (en) * 2010-12-23 2017-07-19 Shell Internationale Research Maatschappij B.V. Gene disruptants producing fatty acyl-coa derivatives
EP3263127B1 (en) 2011-05-23 2019-08-21 Yeda Research and Development Co. Ltd Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US20140271666A1 (en) * 2013-03-14 2014-09-18 Immune Pharmaceuticals Ltd. Use of anti-eotaxin antibodies for treating inflammatory bowel disease
CN104045703B (en) * 2013-03-15 2021-04-06 深圳君圣泰生物技术有限公司 Polypeptide, polypeptide derivative, medicinal salt of polypeptide and medicinal composition
US8802633B1 (en) 2013-03-18 2014-08-12 Board Of Regents, The University Of Texas System Autophagy-inducing peptide analogs
HUE049261T2 (en) * 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd Isolated polypeptides of cd44 and uses thereof
US9453061B2 (en) 2014-08-06 2016-09-27 Brown University Method and compositions for treatment of calcineurin-related diseases
CA3172682A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
WO2017011338A1 (en) 2015-07-10 2017-01-19 President And Fellows Of Harvard College Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use
JP7395517B2 (en) 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド Peptide compounds and their therapeutic uses
IL272074A (en) 2020-01-15 2021-07-29 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Also Published As

Publication number Publication date
ZA202100587B (en) 2022-07-27
BR112020024748A2 (en) 2021-03-23
WO2020012478A2 (en) 2020-01-16
MX2021000264A (en) 2021-05-12
IL280101A (en) 2021-03-01
CO2021001290A2 (en) 2021-02-26
US11912790B2 (en) 2024-02-27
CA3100961A1 (en) 2020-01-16
US20210261615A1 (en) 2021-08-26
JP2021531246A (en) 2021-11-18
AU2019300567A1 (en) 2021-02-25
CN112351989B (en) 2024-03-26
KR20210045397A (en) 2021-04-26
JP7395517B2 (en) 2023-12-11
EA202190249A1 (en) 2021-05-21
JP2024026217A (en) 2024-02-28
CN112351989A (en) 2021-02-09
EP3820882A2 (en) 2021-05-19
WO2020012478A3 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
IL256515A (en) Therapeutic peptides and methods of use thereof
IL292810A (en) Therapeutic compounds and methods of use
PT3656782T (en) Peptide amide compound and preparation method and medical use thereof
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
EP3688011A4 (en) Peptide compositions and methods of use thereof
ZA202003387B (en) Antimicrobial peptides and methods of using same
IL286079A (en) Imidazolonylquinoline compounds and therapeutic uses thereof
GB201715194D0 (en) Compounds and their therapeutic use
ZA202100587B (en) Peptide compounds and therapeutic uses of same
IL272050A (en) Synthetic proteins and therapeutic uses thereof
EP3313427A4 (en) Therapeutic peptides and methods of use thereof
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
GB201804098D0 (en) Novel compounds and therapeutic uses thereof
GB201918541D0 (en) Therapeutic compounds and their use
IL282157A (en) Compounds and therapeutic uses thereof
IL281091A (en) Peptide therapeutics for the treatment of cancer and uses thereof
GB201816553D0 (en) Novel compounds and therapeutic uses thereof
EP4025585A4 (en) Modified peptides and associated methods of use
EP3801592A4 (en) Cyclic peptide compounds and methods of use thereof
ZA202106250B (en) Therapeutic uses of dulaglutide
IL270460B1 (en) Novel compounds and therapeutic uses thereof
GB201813312D0 (en) Compounds and their therapeutic use
GB201905520D0 (en) Compounds and their therapeutic use
GB201715500D0 (en) Crystal forms of therapeutic compounds and dosage forms thereof